

# COMPASS Pathways to participate in Cowen and Roth investor conferences

2022-03-02

LONDON, March 02, 2022 (GLOBE NEWSWIRE) -- COMPASS Pathways plc (Nasdaq: CMPS), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, announced today that members of its management team will participate in and attend one-on-one meetings at two investor conferences as follows:

- Cowen 42<sup>nd</sup> Annual Health Care Conference: “Neuropsych” panel at 9:10am ET on 7 March 2022
- Roth 34<sup>th</sup> Annual Conference: fireside chat at 9:30am ET on 14 March 2022

Webcasts of the Cowen panel discussion and Roth fireside chat will be available on the “Events” page of the Investors section of the COMPASS website. A replay of the webcasts will be available for 30 days following the event. For more information, please visit [ir.compasspathways.com](http://ir.compasspathways.com).

## About COMPASS Pathways

COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. Our focus is on improving the lives of those who are suffering with mental health challenges and who are not helped by current treatments. We are pioneering the development of a new model of psilocybin therapy, in which our proprietary formulation of synthetic psilocybin, COMP360, is administered in conjunction with psychological support. COMP360 has been designated a Breakthrough Therapy by the US Food and Drug Administration (FDA), for treatment-resistant depression (TRD), and we have completed a phase IIb clinical trial of psilocybin therapy for TRD, in 22 sites across Europe and North America. This was the largest randomised, controlled, double-blind psilocybin therapy clinical trial ever conducted, and our topline data showed a statistically significant ( $p < 0.001$ ) and clinically relevant improvement in depressive symptom severity after three weeks for patients who received a single high dose of COMP360 psilocybin with psychological support. We are

also running a phase II clinical trial of COMP360 psilocybin therapy for post-traumatic stress disorder (PTSD). COMPASS is headquartered in London, UK, with offices in New York and San Francisco in the US. Our vision is a world of mental wellbeing. [www.compasspathways.com](http://www.compasspathways.com).

#### Availability of other information about COMPASS Pathways

Investors and others should note that we communicate with our investors and the public using our website ([www.compasspathways.com](http://www.compasspathways.com)), our investor relations website ([ir.compasspathways.com](http://ir.compasspathways.com)), and on social media (LinkedIn), including but not limited to investor presentations and investor fact sheets, US Securities and Exchange Commission filings, press releases, public conference calls and webcasts. The information that we post on these channels and websites could be deemed to be material information. As a result, we encourage investors, the media, and others interested in us to review the information that is posted on these channels, including the investor relations website, on a regular basis. This list of channels may be updated from time to time on our investor relations website and may include additional social media channels. The contents of our website or these channels, or any other website that may be accessed from our website or these channels, shall not be deemed incorporated by reference in any filing under the Securities Act of 1933.

#### Enquiries

Media: Tracy Cheung, [tracy@compasspathways.com](mailto:tracy@compasspathways.com), +44 7966 309024

Investors: Stephen Schultz, [stephen.schultz@compasspathways.com](mailto:stephen.schultz@compasspathways.com), +1 401 290 7324